The annual INTEREST Conference is the premier scientific conference for HIV in Africa and brings together scientists involved in HIV treatment, pathogenesis, and prevention research from around the world.
Hundreds of thousands of people continue to die from advanced HIV, also known as AIDS, because countries are still ill-equipped to detect and treat people suffering through advanced stages of the disease, according to a new report re
Viral load (VL) scale-up efforts have largely focused on laboratory systems, with less attention on facility-level strengthening of staff who facilitate VL testing. To address this gap we implemented a quality improvement (QI) program at 13 health facilities in central and southern Malawi.
In 2019, the HIV pandemic is growing and soon over 40 million people will be living with HIV. Effective population-based approaches to decrease HIV incidence are as relevant as ever given modest reductions observed over the past decade.
Scientists who announced the discovery of a new subtype of HIV earlier this month are telling people not to worry: The discovery, they say, is a good thing and shows that the technology used to make it will improve surveillance of the (admittedly, mutating) virus, but it doesn't mean that HIV wil
The third blog in this ACCESS PrEP blog series addresses health providers’ experiences with oral PrEP services. It explores their knowledge of oral PrEP and concerns about increased risky behaviour. Health providers also expressed concern about the challenges clients faced when accessing oral PrEP and the barriers to uptake, adherence and continuation.
This narrative, the second in the ACCESS PrEP blog series, focuses on PrEP-related side effects. It highlights the determination of some clients to continue using oral PrEP despite the side effects they were experiencing.